Table of Contents

State/Territory Name: MN

State Plan Amendment (SPA) #: 19-0018

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) Summary Form (with 179-like data)
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-14-26 Baltimore, Maryland 21244-1850



Center for Medicaid and CHIP Services

Disabled and Elderly Health Programs Group

April 20, 2020

Mr. Matt Anderson Medicaid Director Minnesota Department of Human Services 540 Cedar Street P.O. Box 64983 St. Paul, Minnesota 55164-0983

Dear Mr. Anderson:

The CMS Division of Pharmacy team has reviewed Minnesota State Plan Amendment (SPA) 19-0018 received in the CMS Division of Program Operations on December 31, 2019. This SPA proposes to allow the state to comply with the Medicaid Drug Utilization Review (DUR) provisions included in Section 1004 of the Substance Use-Disorder Prevention that promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act (P.L. 115-271).

Based on the information provided and consistent with the regulations at 42 CFR 430.20, we are pleased to inform you that SPA 19-0018 is approved with an effective date of October 1, 2019. A copy of the signed CMS-179 form, as well as the pages approved for incorporation into Minnesota's state plan, will be forwarded by the CMS Division of Program Operations.

If you have any questions regarding this request, please contact Lisa Shochet at (410) 786-5445 or Lisa.Shochet@cms.hhs.gov.

Sincerely,

Cynthia R. Denemark, R.Ph. Deputy Director Division of Pharmacy DEHPG/CMCS/CMS

cc: Ann Berg, Deputy Director, Minnesota Department of Human Services James G. Scott, Division Director, CMS Division of Program Operations Ruth A. Hughes, Deputy Division Director, CMS Division of Program Operations Megan Buck, Branch Manager, CMS Division of Program Operations Sandra Porter, CMS Division of Program Operations

PLAN APPROVED - ONE COPY ATTACHED

22. TITLE:

20 SIGNATURE OF REGIONAL OFFICIAL:

Director, Division of Program Operations

10/01/2019

21. TYPED NAME:

23. REMARKS:

James G. Scott

19. EFFECTIVE DATE OF APPROVED MATERIAL:

Citation

1902(a)(85) and Section 1004 of the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act)

- K. Review and Limitations for Opioid Claims. The state will perform the following reviews and actions for claims related to opioids:
 - Prospective safety edits on opioid prescriptions for early duplicate, early refills, and fills in excess of clinically appropriate standards.
 - Prospective safety edits to limit maximum daily morphine milligram equivalents (MME) as recommended by clinical guidelines.
 - 3. Ongoing, retrospective reviews on opioid prescriptions in excess of limits.
 - Ongoing, retrospective reviews for concurrent utilization of opioids and benzodiazepines, and concurrent utilization of opioids and antipsychotics.
- L. <u>Programs to Monitor Antipsychotic Medications to Children.</u>
 The state will review prescriptions for antipsychotic agents for appropriateness for all children, including children in foster care, for clinic appropriateness.

M. Fraud and Abuse Identification.

The DUR program includes a process that identifies potential fraud or abuse of controlled substances by enrollees and/or health care providers.

TN No. 19-18 Approval Date: April 20, 2020 Effective Date: October 1, 2019

Supercedes: N/A